Literature DB >> 12665708

Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Nike M M L Stikkelbroeck1, Ad R M M Hermus, Didi D M Braat, Barto J Otten.   

Abstract

UNLABELLED: Fertility in women with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency appears to be reduced. The purpose of this review is to summarize the reported evidence about subfertility in women with CAH and to review the causes of reduced fertility. Compared with a non-CAH female population, pregnancy and live-birth rates are severely reduced in salt-wasting patients, mildly reduced in simple virilizing patients, and normal in nonclassical patients. Several factors have been suggested to contribute to the impaired fertility in CAH females: adrenal overproduction of androgens and progestins (17-hydroxyprogesterone and progesterone), ovarian hyperandrogenism, polycystic ovary syndrome, ovarian adrenal rest tumors, neuroendocrine factors, genital surgery, and psychological factors such as delayed psychosexual development, reduced sexual activity and low maternal feelings. It is obvious that these factors are interrelated. Improving endocrine, surgical, and psychological management could contribute to improving fertility chances in these patients. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING
OBJECTIVES: After completion of this article, the reader will be able to define the various types of CAH, to describe the fertility issues in the CAH patients, to outline the various other causes of hyperandrogenism, and to list the treatment options for the patient with CAH.

Entities:  

Mesh:

Year:  2003        PMID: 12665708     DOI: 10.1097/01.OGX.0000062966.93819.5B

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  20 in total

Review 1.  Adrenal steroidogenesis and congenital adrenal hyperplasia.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06       Impact factor: 4.741

Review 2.  Impact of Exogenous Testosterone on Reproduction in Transgender Men.

Authors:  Molly B Moravek; Hadrian M Kinnear; Jenny George; Jourdin Batchelor; Ariella Shikanov; Vasantha Padmanabhan; John F Randolph
Journal:  Endocrinology       Date:  2020-03-01       Impact factor: 4.736

Review 3.  Intrauterine environment and polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Mark O Goodarzi; Gregorio D Chazenbalk; David H Abbott
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

Review 4.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 5.  Congenital adrenal hyperplasia in pregnancy: approach depends on who is the 'patient'.

Authors:  Erin Keely; Janine Malcolm
Journal:  Obstet Med       Date:  2012-09-24

Review 6.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

7.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

8.  Long-Term Gynecological Outcomes in Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  T H Johannsen; C P L Ripa; E Carlsen; J Starup; O H Nielsen; M Schwartz; K T Drzewiecki; E L Mortensen; K M Main
Journal:  Int J Pediatr Endocrinol       Date:  2010-10-20

Review 9.  [Congenital adrenal hyperplasia and growth hormone deficiency. Special care in transition to adulthood].

Authors:  H G Dörr; C Schöfl
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

Review 10.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.